Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Social Psychology Clear all
Completed No phase listed Observational

A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study

NCT01974999
View directory record Official record
Conditions
Kidney Disease, Kidney Failure, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 2:32 PM EDT
Recruiting Phase 4 Interventional

Empagliflozin Treatment in Kidney Transplant Recipients

NCT06013865
View directory record Official record
Conditions
Kidney Transplant, Chronic Kidney Disease
Interventions
Empagliflozin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 6, 2026, 2:32 PM EDT
Recruiting No phase listed Observational

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

NCT07434869
View directory record Official record
Conditions
Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Interventions
Not listed
Lead sponsor
Brian Keller
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 6, 2026, 2:32 PM EDT
Completed No phase listed Observational

Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction

NCT01140152
View directory record Official record
Conditions
Intestinal Transplant, Cellular Rejection
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 6, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

NCT00492869
View directory record Official record
Conditions
Kidney Transplantation
Interventions
AEB071
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 6, 2026, 2:32 PM EDT
Completed No phase listed Observational Results available

A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation

NCT03611621
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Imlifidase
Drug
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 6, 2026, 2:32 PM EDT
Completed No phase listed Observational

Clinical Trials in Organ Transplantation Extension Study

NCT04126746
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 6, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

NCT00782821
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Rabbit Antithymocyte Globulin, Velcade, Rituxan
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 6, 2026, 2:32 PM EDT
Completed No phase listed Observational

Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)

NCT02109575
View directory record Official record
Conditions
Cardiovascular Disease, Acute Rejection of Cardiac Transplant, Cardiac Transplant Rejection, Heart Transplant Failure and Rejection
Interventions
Blood Draw of up to 10 ml
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 6, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Study of Glycemic Control on Liver Transplantation Outcomes

NCT01211730
View directory record Official record
Conditions
Evidence of Liver Transplantation, Hyperglycemia, Rejection
Interventions
Insulin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 6, 2026, 2:32 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of Platelet Rich Plasma on Pain at Skin Graft Donor Sites

NCT03937765
View directory record Official record
Conditions
Skin Graft (Allograft) Rejection, Skin Graft Complications, Skin Graft Detachment, PRP
Interventions
PRP harvest and preparation
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 6, 2026, 2:32 PM EDT
Completed No phase listed Observational

AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

NCT04057742
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
AlloSure ddcfDNA assay, AlloMap assay, Inflammatory Cytokines, Immune Cell Phenotypes
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 6, 2026, 2:32 PM EDT
Recruiting No phase listed Observational

GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation

NCT07516379
View directory record Official record
Conditions
Lung Transplant, End Stage Lung Disease, Rejection
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 6, 2026, 2:32 PM EDT
Terminated Not applicable Interventional

Goal of Open Lung Ventilation in Donors

NCT03439995
View directory record Official record
Conditions
Brain Death, Organ Donation, Organ Transplant Failure or Rejection
Interventions
Open lung protective ventilation, Conventional ventilation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 6, 2026, 2:32 PM EDT
Withdrawn Phase 2 Interventional

Selective CD28 Blockade in Renal Transplant Recipients

NCT04903054
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplant Recipients
Interventions
Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 6, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

NCT00117689
View directory record Official record
Conditions
Liver Dysfunction, Rejection, Transplant, Transplantation, Liver
Interventions
Thymoglobulin, Corticosteroid, Tacrolimus, Mycophenolate Mofetil
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 6, 2026, 2:32 PM EDT
Completed No phase listed Observational

Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection

NCT01985412
View directory record Official record
Conditions
Cardiac Transplant Rejection, Lung Transplant Rejection
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Santa Clara, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 6, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional

24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients

NCT00555789
View directory record Official record
Conditions
Kidney Transplantation
Interventions
AEB071, mycophenolic plus tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 6, 2026, 2:32 PM EDT
Completed Not applicable Interventional Results available

AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm

NCT04758637
View directory record Official record
Conditions
Opioid Abuse
Interventions
Overdose Notification
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 6, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients

NCT00299221
View directory record Official record
Conditions
Immunosuppression
Interventions
Tacrolimus, combination therapy
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 6, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 6, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

NCT00275509
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 6, 2026, 2:32 PM EDT
Active, not recruiting Phase 4 Interventional

Envarsus XR® in Adolescent Renal Transplant Recipients

NCT03266393
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Grafting, Kidney
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 6, 2026, 2:32 PM EDT
Active, not recruiting Not applicable Interventional

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

NCT06414603
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
The Prospera™ Test
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 6, 2026, 2:32 PM EDT